WO1994023734A1 - Method of treatment of diseases by deletion of t cells - Google Patents
Method of treatment of diseases by deletion of t cells Download PDFInfo
- Publication number
- WO1994023734A1 WO1994023734A1 PCT/US1994/003861 US9403861W WO9423734A1 WO 1994023734 A1 WO1994023734 A1 WO 1994023734A1 US 9403861 W US9403861 W US 9403861W WO 9423734 A1 WO9423734 A1 WO 9423734A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- sea
- deletion
- superantigen
- cell
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/085—Staphylococcus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- this invention describes a method of treating diseases mediated by T cells of V ⁇ type by deletion of specific T cell populations.
- This invention is premised on the discovery that chronic exposure to a superantigen causes almost complete deletion of target T cells in vivo.
- T cells are a heterogeneous population of cells derived from the thy us which circulate through the blood and lymphatic vessels of the body. They function to detect and react against foreign invaders through a recognition system called the T cell antigen receptor (TCR) . T cells respond to foreign antigens presented in the context of molecules of the major histocompatibility complex (MHC) or to non-self MHC molecules by proliferating and by the generation of effector cells with helper or cytolytic functions (Borst et al. (1987) J. Immunol. 139.1952) .
- MHC major histocompatibility complex
- cytolytic functions helper or cytolytic functions
- helper T cells Before helper T cells can recognize conventional protein antigens, the proteins must first undergo processing by macrophages or other antigen-presenting cells. These cells essentially swallow antigens and chop them into peptides. The presenters then display the peptide antigens at the cell surface in combination with MHC molecules. Once an antigen is displayed, the few helper T cells in the body that bear receptors for that particular peptide link up with it.
- the TCR consist of two proteins chains, and ⁇ , each chain containing a constant and a variable domain.
- the variable domains are encoded in two ( ⁇ ) or three ( ⁇ ) different gene segments (variable (V) , diversity (D) , and joining (J) ) (Siu et al. (1984) Cell r7:393; Yanagi et al. (1985) Proc. Natl. Acad. Sci. USA .82..3430).
- V, D, and J domains of both the and ⁇ chains participates in antigen recognition in a manner which is uniquely characteristic of that T cell and defines a unique binding site.
- T cell TCR diversity is created through somatic rearrangement (Yanagi et al. (1984) Nature 308:145; Hedrick (1984) Nature 308:149; Siu et al.
- SAg superantigens
- SAg bind to lateral faces of both the TCR and MHC molecules, forming a bridge between these cell-surface molecules on apposing cells.
- Selective activation of T cells by SAg is determined primarily by the -I ⁇ element of the TCR of the responding cells, independent of the specificity of that receptor for any particular MHC- processed antigen.
- Viral sources include the endogenous and exogenous mouse mammary tumor viruses (MMTV) , which have been shown to have strong effects on the T cell repertoire in the mouse (Acha- Orbea et al. (1991) Nature 350:207; . Dyson et al.
- MMTV mouse mammary tumor viruses
- Superantigens may contribute to autoimmune diseases, in which components of the immune system attack normal tissue.
- the process of deletion of T cells responsive to self, potentially harmful self- reactive T cells, is called tolerance or negative selection (Kappler et al. (1987) Cell 1-9:273; Kappler et al. (1988) Nature 332:35; MacDonald et al. (1988)
- T cells bearing certain VS types have been implicated in various autoimmune conditions, including arthritis and multiple sclerosis. These findings imply that the destructive cells might be activated by a superantigen that binds to the identified V0 types (Paliard et al. (1991) supra; Johnson et al. (1992) supra) .
- Autoimmune diseases include a large number of disorders, including such neural diseases as multiple sclerosis and myasthenia gravis, diseases of the joints, such as rheumatoid arthritis, attacks on nucleic acids, as observed with systemic lupus erythematosus, and such other diseases associated with various organs, as psoriasis, juvenile onset diabetes, Sj ⁇ gren's disease, and thyroid disease. These diseases can have a variety of symptoms, which can vary from minor and irritating to life-threatening. For example, rheumatoid arthritis (RA) is a chronic, recurrent inflammatory disease primarily involving joints, and affects 1-3% of North Americans, with a female to male ration of 3:1.
- RA rheumatoid arthritis
- Severe RA patients tend to exhibit extra-articular manisfestations including vasculitis, muscle atrophy, subcutaneous nodules, lymphadenopathy, splenomegaly, and leukopenia. It is estimated that about 15% of RA patients become completely incapacitated.
- USSN 07/827,540 filed January 28, 1992, entitled: Method for modifying T cell response, hereby specifically incorporated by reference, describes a method of treating superantigen-mediated diseases.
- Pre-exposure of an animal to a mutated superantigen molecule such as Staphylococcal enterotoxin B (SEB) conferred protection against subsequent exposure to the deleterious effects of the wild-type toxin.
- SEB Staphylococcal enterotoxin B
- the mutated superantigen molecule modifies the T-cell response to the wild-type toxin without modifying the B-cell response.
- PCT/US93/00839 filed January 28, 1993, entitled: Protective effects of mutated superantigens. hereby specifically incorporated by reference, further describes the protective effects of mutated superantigens and their ability to selectively delete or inactivate specific T-cell populations.
- SEB Staphylococcal enterotoxin B
- the present invention is premised on the discovery that specific T cell populations can be deleted without prior induction of T cell proliferation. This discovery may be applied in the treatment of diseases mediated by V3-bearing T cells.
- SAg superantigen
- SEA Staphylococcal enterotoxin A
- This invention includes a method for treating diseases mediated by T cells bearing specific V3 elements comprising causing the deletion of said T cell populations without prior induction of said T cell populations.
- the method of the present invention includes the administration of substances that inhibit specific V/3 elements, including antibodies to specific V/3 elements. This discovery may also be used to achieve peripheral tolerance to low levels of antigen without prior cell division.
- the present invention includes a method for inducing tolerance to peripherally expressed self antigens comprising chronic intraperitoneal administration of a low dose of a superantigen which does not result in induction of T cell proliferation.
- FIGURE 1 depicts the level of V/33 or V/311 use in CD4 + or CD8 + T cells from the lymph nodes, mesenteric lymph nodes, blood, and spleen, for up to 20 days after a single dose of SEA.
- B10.BR/SgSnJ mice were given 0.78(o), 3.1( «) . 12.5(A) , or 50(B) ug SEA i.v. in 0.2 ml basal salt solution (BSS) on day 0.
- BSS basal salt solution
- Control BSS alone
- FIGURE 1A-1D show the level of V33 use in CD4 + T cells.
- FIGURE 1E-1H show V/33 use among CD8 + T cells.
- FIGURE 1I-1L show V/311 use among CD8 + T cells.
- FIGURE 2 depicts the expression of V/33 following acute exposure to low levels of SEA. BlO.BR/SgSnJ mice received 0.008(°), 0.04(») , 0.2(A) , or 1.0(B) ug of SEA i.v. in 0.2 ml BSS.
- FIGURE 2A shows V/33 use in CD4 + lymph node T cells.
- FIGURE 2B shows V/33 use in CD8 + lymph node T cells.
- FIGURE 3 depicts the depletion of V/?3-bearing T cells as a result of chronic exposure to SEA.
- FIGURE 3A-3D show V/33 use among CD4 + T cells.
- FIGURE 3E-3H show V/314 use among CD4 + T cells.
- FIGURE 3I-3L show V/33 use among CD8 + T cells.
- FIGURE 3M-3P show V/311 use among CD8 + T cells.
- FIGURE 3Q-3T show V/314 use among CD8 + T cells.
- the present invention includes a method for treating diseases mediated by T cells bearing specific V3 elements by causing the deletion of those T cell populations.
- diseases mediated by specific V/3-bearing T cells are treated by the deletion of those T cell populations — without prior induction of T cell proliferation — by chronic intraperitoneal administration of low doses of superantigen.
- diseases mediated by specific V/3-bearing T cells are treated by the administration of substances inhibitory to specific V/3 elements, such as by the administration of V / 0 antibodies.
- mice that were either acutely or chronically exposed to varying doses of SEA, and the relative level of T cells bearing SEA-reactive V/3 elements was followed over time in lymphocytes purified from peripheral blood, lymph nodes, mesenteric lymph nodes, and the spleen.
- Acute exposure caused the disappearance of 50-70% of reactive T cells.
- Chronic exposure caused almost complete deletion of target T cells. Deletion was evident even in animals treated with very low doses of SEA, doses too small to cause any apparent T cell proliferation.
- proliferation does not appear to be a prerequisite for peripheral deletion of T cells and peripheral tolerance may be achieved by chronic exposure to low levels of antigen without prior cell division.
- the present discovery may also be used as a method for inducing tolerance to peripherally expressed self antigens.
- One embodiment of the present invention includes an extensive characterization of T cell proliferation and deletion induced by the exogenous SAg SEA.
- Different doses of SEA were administered in either a single (acute) injection or repeated (chronic) doses. Proportionate use of several different TCR elements was followed over time in several different lymphoid compartments, for both CD4- and CD8-bearing T cells.
- a surprising finding of the present invention is that repeated administration of SEA, even in very small amounts, effectively deleted T cells bearing reactive V / 3 elements ("target" V/3 elements) in the apparent absence of prior proliferation.
- target V/3 elements reactive V / 3 elements
- V/3 footprint usually consists of elevated levels of certain V/3 elements. Although the role of the elevated V / 3 populations in the etiology of these diseases is not known, it must be assumed that the V/3 specific population plays some role in the mediation of the disease or medical condition.
- the present invention provides a method for reducing levels of T-cell populations having a specific V/3 element.
- the present invention may be used to advantage in several ways.
- the chronic administration of a superantigen will delete the same population of V/3 elements that are expanded by the exposure to relatively large quantities of the superantigen.
- the chronic low level administration can serve, therefore, as a type of vaccination to the superantigen itself.
- the superantigen giving rise to or mediating the given disease or medical condition is not known.
- the V/3 "footprint" of the disease is known, it is possible to select one of the known superantigens that has common V/3 elements in its footprint.
- the present invention anticipates the administration to a patient of a SAg to reduce certain T cell populations containing a given V/3 element.
- the V / 8 element that will be effected will correspond to the V / 3 element (or elements) that is activated upon exposure to a large dose of the SAg.
- the chronic administration of a natural SAg may lead to the deletion of T cell populations containing V / 3 elements that are not effected by larger doses of the SAg.
- the present invention includes the administration of modified and mutated superantigens.
- modified and mutated superantigens are described in detail in U.S. patent application serial number 07/827,540 filed January 28, 1992 entitled “Method for Modifying T Cell Response”, and PCT application PCT/US93/00839, filed January 28, 1993, entitled “Protective Effects of Mutated Superantigens”. Both of these applications are specifically incorporated herein by reference. Again, it is anticipated that certain modified and mutated superantigens will have the ability to delete certain T cell populations based on common V / S elements.
- the T cell populations deleted upon chronic administration of the mutated superantigen will be the same as would be deleted upon chronic administration of the non mutated superantigen.
- the mutations will alter the specificity of the superantigen and T cell populations with different V / ⁇ elements will be deleted. It would be well within the skill and knowledge of one skilled in the art to analyze the mutated superantigens to determine which T cell populations will be deleted by the chronic administration of such mutated superantigens.
- diseases having a specific V / 3 footprint generally superantigen initiated or mediated diseases — may be prevented or treated by the administration of a superantigen in a manner that leads to the deletion of certain V / 3 populations without any initial T-cell proliferation.
- the superantigen is administered chronically in low dosages. "Chronically” is defined as more than one administration, and more specifically, is generally meant to include periodic administrations (e.g., hourly, twice daily, daily, weekly, etc.) for a period of time sufficient to lead to T-cell V/3 specific deletion.
- low dosages is meant a dosage of superantigen of less than 100 ug/kg, and preferably less than 50 ug/kg. Since the amount of superantigen necessary to lead to deletion without causing initial T-cell proliferation may very among the superantigens, the low level of dosage may be defined as anything less than the amount of superantigen administration that gives rise to T-cell proliferation.
- the method of the present invention includes therapeutic compositions of superantigen which may be administered parenterally by injection, although other effective administration forms, such as intraarticular injection, inhalant mists, orally active formulations, transdermal iontophoresis or suppositories, are also envisioned.
- One preferred carrier is physiological saline solution, but it is contemplated that other pharmaceutically acceptable carriers may also be used.
- the carrier and the superantigen constitute a physiologically-compatible, slow-release formulation.
- the primary solvent in such a carrier may be either aqueous or non-aqueous in nature.
- the carrier may contain other pharmacologically-acceptable excipients for modifying or maintaining the pH, osmolarity, viscosity, clarity, color, sterility, stability, rate of dissolution, or odor of the formulation.
- the carrier may contain still other pharmacologically-acceptable excipients for modifying or maintaining the stability, rate of dissolution, release, or absorption of the superantigen.
- excipients are those substances usually and customarily employed to formulate dosages for parenteral administration in either unit dose or multi-dose form.
- the therapeutic composition may be stored in sterile vials as a solution, suspension, gel, emulsion, solid, or dehydrated or lyophilized powder.
- Such formulations may be stored either in a ready to use form or requiring reconstitution immediately prior to administration.
- the preferred storage of such formulations is at temperatures at least as low as 4°C and preferably at -70°C. It is also preferred that such formulations containing the superantigen are stored and administered at or near physiological pH. It is presently believed that administration in a formulation at a high pH (i.e. greater than 8) or at a low pH (i.e. less than 5) is undesirable.
- the manner of administering the formulations containing superantigen for systemic delivery is via subcutaneous, intramuscular, intravenous, intranasal or vaginal or rectal suppository.
- administration is by intraperitoneal injection.
- acute exposure chronic exposure to
- SEA resulted ultimately in the almost complete disappearance of all CD4 + and CD8 + T cells bearing V / 33 in all tissues analyzed. This result was seen at all doses of SEA tested. As discussed above, since the disappearance occurred in all organs tested, it did not reflect a redistribution of V/33 + cells. The disappearance occurred far too quickly to be explained by thymic depletion (i.e., the death of SEA-reactive cells in the thymus, with the subsequent dilution of the peripheral pool of mature T cells) .
- V/33 and V/311 Two V/3 elements (V/33 and V/311) have previously been characterized as SEA-reactive (Callahan et al. (1990) J. Immunol. 4_4:2473). Treatment with SEA had slightly different effect on T cells bearing V / 311 rather than V/33. CD8 + /V / 311-bearing cells did not increase in numbers as much as CD8 + /V/33-bearing cells during chronic treatment with the lowest doses of SEA, nor were the V/311 * cells as effectively deleted.
- This difference may simply reflect a lower affinity of SEA for V / 311 than for V/33, as the toxins have been shown to have varying affinities for their different V / 3 targets (Fleischer and Schrezenmeier (1988) J. Exp. Med.
- V/311 + T cells to SEA should be shifted with respect to that of V33-bearing cells; however, this was not the observed result.
- Chronic SEA treatment did not cause overwhelming deletion of CD8 + /V/311 + T cells at any dose, even though higher doses caused excellent initial expansion of such cells.
- the difference in response of V/311-bearing cells may be due to the fact that B10.BR mice contain at least one MTV which expresses an endogenous V/311-reactive SAg (Woodland et al. (1991) supra; Bill et al. (1989) J. Exp.
- CD8 + /V/311 + cells in the B10.BR mouse are refractory to SEA-mediated deletion because they are in an unusual state of activation or anergy due to the expression of MTV-9 (and perhaps MTV-8) encoded SAgs.
- the effects of these Class II-associated bacterial SAgs on the CD4 + and CD8 + T cell populations were similar, there were some subtle differences in the responses to SEA of these two types of cells.
- the CD4 + cells did not disappear as rapidly as the CD8 + cells during chronic treatment with SEA.
- these differences are related to the ability or inability of the accessory molecules CD4 or CD8 to join the TCR/SAg/Class II complex, where these accessory molecules could serve to enhance the stability of the interactions within the complex, and/or to provide secondary intracellular signals to the responding T cell.
- the two subsets of cells simply have inherently different thresholds of activation - in effect, they could be "programmed" to respond differently to marginal or suboptimal signals.
- T cells bearing V / 33 expanded slightly in spleen but not lymph nodes in response to chronic i.p. treatment with low amounts of SEA. This observation could be due to migration of these cells to the spleen from other locations or to uneven distribution of SEA in these animals.
- the activation state of T cell populations in different lymphoid compartments may differ, leading to differences in their responses to marginal levels of SAg.
- a related possibility is that the antigen- presenting cells found in different locations deliver different ancillary signals, resulting in differences in the response of SAg-reactive T cells. The present data do not distinguish between the possibilities.
- Example 1 describes the materials and method of the present invention.
- Example 2 describes the result of acute exposure of mice to the superantigen toxin SEA on V / 3 use.
- Example 3 describes the effects of chronic superantigen administration on target V/3 expression, and shows that extremely low doses of SEA given chronically preferentially deleted a specific population of V / 3 T cells.
- mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and housed in the animal care facilities of the National Jewish Center for Immunology and Respiratory Medicine. Mice were between 6 and 12 weeks of age.
- animals were given a single dose of SEA, administered intravenously (i.v.) in 0.2 ml balanced salts solution (BSS) ; the injection date was day 0.
- SEA was administered intraperitoneally (i.p.) every other day in 0.2 ml BSS, starting on day 0.
- mAbs monoclonal antibodies to mouse antigens were used in analysis of the TCR repertoire: GK1.5, rat an i-CD4 (Dialynas et al. (1983) J. Immunol. 133:2445) ; rat anti-CD8 (Ledbetter and Herzenberg (1979) Immunol. Rev. 4-7:63; KJ25-606.7, hamster anti-V/33 (Pullen et al. (1988) Nature 335:796) . 14-2, rat anti-V/314 (Liao et al. (1989) J. Exp. Med. 170:135), RR3-15, rat anti-V/311 (Bill et al.
- mice were tail-bled, the blood collected into BSS containing 1% heparin, then mice were sacrificed by cervical dislocation.
- Peripheral lymph nodes (inguinal, brachial and axillary) , mesenteric lymph nodes, and spleen were harvested separately. Lymphocytes were released from organs by passage through nylon mesh.
- Peripheral blood and spleen samples were treated with buffered ammonium chloride to lyse erythrocytes, followed by two washes with BSS. All samples were passed over nylon wool (Julius et al. (1973) Eur. J. Immunol.
- T cells bearing a given V/3 element were determined relative to net ⁇ / 3 + cells.
- CD4 and CD8 usage it was assumed that cells which stained positive for TCR but not CD8 were CD4 + , and that conversely, TCR + cells negative for CD4 were CD8*.
- the sum of (CD4 + ) and (CD8 + ) cells in a sample matched the net a ⁇ TCR * cells to within 1- 2%.
- Proportional use of specific V/3 elements within the CD4 + population was calculated from the ratio of
- Staphylococcal enterotoxin A was purchased from Toxin Technologies (Madison, WI) . Lyophilized material was resuspended in balanced salt solution (BSS) and sterilized by filtration.
- BSS balanced salt solution
- mice were challenged with continuous, low-level doses of SAg.
- V/33-bearing T cells began to drop in percentage as early as day 2 in the mesenteric lymph nodes and peripheral blood of mice given 0.04 or 0.008 ug SEA every other day although V / 33-bearing CD4 + cells still did increase in percentage somewhat in spleen prior to their deletion.
- T cells bearing target V/3s caused by chronic exposure to SEA are not permanent.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP6523320A JPH08508752A (en) | 1993-04-08 | 1994-04-08 | Method of treating disease by elimination of T cells |
EP94912969A EP0692969A4 (en) | 1993-04-08 | 1994-04-08 | Method of treatment of diseases by deletion of t cells |
AU65307/94A AU6530794A (en) | 1993-04-08 | 1994-04-08 | Method of treatment of diseases by deletion of t cells |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4549493A | 1993-04-08 | 1993-04-08 | |
US08/045,494 | 1993-04-08 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994023734A1 true WO1994023734A1 (en) | 1994-10-27 |
Family
ID=21938212
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1994/003861 WO1994023734A1 (en) | 1993-04-08 | 1994-04-08 | Method of treatment of diseases by deletion of t cells |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0692969A4 (en) |
JP (1) | JPH08508752A (en) |
AU (1) | AU6530794A (en) |
CA (1) | CA2159891A1 (en) |
WO (1) | WO1994023734A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9528088B2 (en) | 2002-06-28 | 2016-12-27 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7310491A (en) * | 1990-02-23 | 1991-09-18 | Immulogic Pharmaceutical Corporation | Superantigen induced immune non-responsiveness |
-
1994
- 1994-04-08 WO PCT/US1994/003861 patent/WO1994023734A1/en not_active Application Discontinuation
- 1994-04-08 EP EP94912969A patent/EP0692969A4/en not_active Withdrawn
- 1994-04-08 CA CA002159891A patent/CA2159891A1/en not_active Abandoned
- 1994-04-08 JP JP6523320A patent/JPH08508752A/en active Pending
- 1994-04-08 AU AU65307/94A patent/AU6530794A/en not_active Abandoned
Non-Patent Citations (6)
Title |
---|
Cell, Vol. 49, issued 24 April 1987, J.W. KAPPLER et al., "A T Cell Receptor V-beta Segment that Imparts Reactivity to a Class II Major Histocompatibility Complex Product", see pages 263-271, especially the Abstract. * |
Cell, Vol. 54, issued 12 August 1986, J.L. URBAN et al., "Restricted use of T Cell Receptor V Genes in Murine Autoimmune Encephalomyelitis Raises Possibilities for Antibody Therapy", see pages 577-592, especially the Abstract. * |
Cell, Vol. 54, issued 15 July 1988, H. ACHA-ORBEA et al., "Limited Heterogeneity of T Cell Receptors from Lymphocytes Mediating Autoimmune Encephalomyelitis allows Specific Immune Intervention", see pages 263-273, especially the Abstract. * |
Cell, Vol. 56, issued 13 January 1989, J. WHITE et al., "The V-beta-specific Superantigen Staphylococcal Enterotoxin B: Stimulation of Mature T Cells and Clonal Deletion in Neonatal Mice", see pages 27-35, especially the Abstract. * |
J. Exp. Med., Vol. 172, issued October 1990, B.L. RELLAHAN et al., "In Vivo Induction of Anergy in Peripheral V-beta8 + T Cells by Staphylococcal Enterotoxin B", see pages 1091-1100, especially the summary. * |
See also references of EP0692969A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9528088B2 (en) | 2002-06-28 | 2016-12-27 | Life Technologies Corporation | Methods for eliminating at least a substantial portion of a clonal antigen-specific memory T cell subpopulation |
Also Published As
Publication number | Publication date |
---|---|
CA2159891A1 (en) | 1994-10-27 |
AU6530794A (en) | 1994-11-08 |
EP0692969A4 (en) | 1997-08-20 |
EP0692969A1 (en) | 1996-01-24 |
JPH08508752A (en) | 1996-09-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Wofsy et al. | Reversal of advanced murine lupus in NZB/NZW F1 mice by treatment with monoclonal antibody to L3T4. | |
Kupiec-Weglinski et al. | Interleukin 2 receptor-targeted therapy—rationale and applications in organ transplantation | |
Abbas et al. | Functional diversity of helper T lymphocytes | |
McCormack et al. | Profound deletion of mature T cells in vivo by chronic exposure to exogenous superantigen. | |
Taylor et al. | Suppressor cells in humoral immunity and tolerance | |
JPH04506512A (en) | Vaccination and methods against diseases caused by pathogenic responses of specific T cell populations | |
EA002966B1 (en) | METHOD FOR TREATING INFLAMMATORY BOWEL SYNDROME, METHOD OF SELECTION OF LT-beta-R BLOCKING AGENT AND METHOD FOR INHIBITING LT-beta-R SIGNALLING | |
JPH10505482A (en) | Ligands for inducing antigen-specific apoptosis in T cells | |
KR0183029B1 (en) | Monoclonal antibodies for inducing tolerance | |
EP0722738A2 (en) | Vaccination and methods against diseases resulting from pathogenic responses by specific T cell populations | |
CN100473417C (en) | Method of modulating memory effector T-cells using CD2-binding agent, and compositions | |
US6326465B1 (en) | Immunomodulatory polypeptides derived from the invariant chain of MHC class II | |
US20040110673A1 (en) | Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases | |
US5643572A (en) | Methods and compositions for the modulation of host immune response to an allergen | |
JPH08500328A (en) | Protective action of mutated superantigen | |
Pingel et al. | Altered ligands reveal limited plasticity in the T cell response to a pathogenic epitope | |
WO1993012814A2 (en) | Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations | |
US20040116338A1 (en) | Use of soluble forms of CD83 and nucleic acids encoding them for the treatment or prevention of diseases | |
AU686134B2 (en) | Soluble T-cell receptor alpha chain and derivatives used as prophylactic and therapeutic agents for autoimmune diseases | |
US6113903A (en) | Peptides and methods against diabetes | |
EP0692969A1 (en) | Method of treatment of diseases by deletion of t cells | |
US6413516B1 (en) | Peptides and methods against psoriasis | |
Myers et al. | Peptide ligand structure and I-Aq binding avidity influence T cell signaling pathway utilization | |
AU697910C (en) | Peptides and methods against psoriasis | |
Kirkham et al. | New approaches for antirheumatic therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1994912969 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 1995 532591 Country of ref document: US Date of ref document: 19950929 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2159891 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1994912969 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1994912969 Country of ref document: EP |